The Thoracic Oncology service at Washington University focuses on the diagnosis and treatment of patients with thoracic malignancies such as lung cancer.

We are actively engaged in conducting clinical trials to improve the outcomes of patients with lung cancer and other thoracic malignancies. Each year, more than 10,000 patients are evaluated and treated by our thoracic medical oncology team.

Make an Appointment

Referring physicians or patients can call 314-747-1171 to schedule a consultation with one of our Thoracic physicians.

Make a gift to Thoracic Medical Oncology Research

Thoracic Malignancies

Our team focuses on lung cancer and other thoracic malignancies including:

  • Non-small cell lung cancer
  • Small cell lung cancer
  • Carcinoid tumors
  • Mesothelioma
  • Thymic malignancies

Our Treatment Approach

The diagnostic and treatment decisions are often made by a multidisciplinary team including thoracic surgeons, radiation oncologists, pathologists and radiologists. During our weekly meetings, all the specialties are involved to assure that the patients receive the best treatment possible.

Our outpatient clinics also include the important participation of clinical pharmacologists, the palliative care team, nutritionists and social workers. The treatment options provided by our thoracic team include:

  • Chemotherapy
  • Immunotherapy
  • Targeted therapy
  • Surgery
  • Radiation therapy

Treatment Team

Daniel Morgensztern

Daniel Morgensztern, MD
Thoracic Medical Oncology Program Director

Research: Thoracic malignancies, immunotherapy, targeted therapy, antibody-drug conjugates and cancer epidemiology.

Maria Quintos Baggstrom, MD

Maria Quintos Baggstrom, MD

Research: Thoracic oncology, medical education, clinical trial methodology

Salman I. Chaudhry

Salman I. Chaudhry, MD

Research: Thoracic and gastrointestinal malignancies

Haobin Chen

Haobin Chen, MD, PhD

Research: Development of new therapies for small cell lung cancer, identification of predictive biomarkers and mechanisms of drug resistance.

Govindan Ramaswamy

Ramaswamy Govindan, MD

Research: Cancer genomics, personalized treatment for early stage and locally advanced non-small cell lung cancer.

Brett Herzog

Brett H. Herzog, MD, PhD

Research: Thoracic malignancies and novel therapeutic strategies targeting the tumor microenvironment

Anjali Rohatgi

Anjali Rohatgi, MD, PhD

Research: Thoracic malignancies and immunotherapy

Saiama Waqar

Saiama N. Waqar, MD, MBBS, MSCI

Research: Personalized treatment of lung cancer including targeted therapies, immunotherapy and antibody-drug conjugates.

Jeffrey Ward

Jeffrey P. Ward, MD, PhD

Research: Thoracic malignancies and immunotherapy.

Advanced Practice Providers
  • Amanda Allen (Ward)
  • Samantha Conlin (Rohatgi) 
  • Mary Ellen Flanagan (Morgensztern) 
  • Hailey Hunter (Waqar, Ward) 
  • Rachel Sanger (Baggstrom, Govindan) 
Nurse Coordinators
  • Kim Benson (Morgensztern) 
  • Christy Breckenridge (Baggstrom) 
  • Lauralea Franklin (Baggstrom, Govindan) 
  • Monica Freund (Waqar)
  • Megan Huniak (Baggstrom, Govindan) 
  • Jessica Litteken (Herzog) 
  • Jill Nickless (Morgensztern) 
  • Madeline Oconnor (Chen) 
  • Krystal Prater (Waqar)
  • Julie Tucker (Chen, Rohatgi)
  • Lee Ann Wasson (Chen) 
  • Lee Ann Wasson (Ward)
  • Mikayla Wilson (Rohatgi)

Research and Clinical Trials

Research plays a pivotal role in our thoracic oncology program. We are deeply committed to both basic and clinical trials aimed at assessing innovative and improved treatments for lung cancer and other thoracic malignancies. At Washington University, we offer numerous clinical trials that explore new and promising therapies for thoracic malignancies, and our contributions were essential to the development of several drugs that have subsequently gained approval.

Our team of basic researchers concentrates on cancer genomics, various forms of immunotherapy, and the tumor microenvironment. These efforts are at the forefront of providing advanced treatment options for our patients. Most of the research in our group has been focused on:

  1. Treatment of early stage lung cancer
  2. Immunotherapy in locally advanced non-small cell lung cancer
  3. Targeted therapy for non-small cell lung cancer
  4. Immunotherapy for non-small cell lung cancer
  5. Novel therapies for small cell lung cancer
Ongoing Clinical Trial Highlights